Singapore, July 17, 2025 (GLOBE NEWSWIRE) -- Basel Medical Group Ltd (Nasdaq: BMGL or the “Company”), today announced that it is putting on hold on the acquisition of BTC digital asset. After thorough discussions, Basel and the consortium of Bitcoin (BTC) holders have mutually agreed to pause the acquisition of digital asset. This decision reflects the ongoing regulatory review of digital assets by US authorities and the current lack of clarity on how forthcoming policies may impact the transaction. Given t ...

Following a thorough review, #Binance Alpha will remove the following tokens on 2025-07-16 at 13:00 (UTC): $LLM, $GNON, $NEUR, $TRISIG.Selling of these tokens on Binance Alpha will still be allowed after removal.Users can do so by:- Selling: Binance Exchange Alpha account: [Asset] tab > [Alpha] tab > Select token > Sell- Trading: Binance Web3 Wallet: [Market] tab > Search > Trade ...

Core Insights - BioAdaptives, Inc. is set to launch NeuroRush™, a nootropic designed to enhance cognitive performance and stress adaptability, with a full commercial release planned for August/September 2025 following successful test market results [1][3] Product Details - NeuroRush™ features a premium adaptogen-based formula that includes six clinically studied ingredients: Rhodiola Rosea, Ashwagandha, Bacopa Monnieri, Panax Ginseng, and Mucuna Pruriens, aimed at providing a balanced experience for high-functioning individuals [2] - The product will be available in two formulations: one with natural caffeine for fast-acting mental energy and a caffeine-free version for those sensitive to stimulants [2] Market Strategy - BioAdaptives plans to distribute NeuroRush™ through select online retailers, direct-to-consumer channels, and strategic health & wellness partners across the nation [4] - Initial consumer feedback indicates that NeuroRush™ is perceived as a high-performance solution that differentiates itself from conventional stimulant-based brain products [4] Company Overview - BioAdaptives, Inc. focuses on developing and marketing science-based natural health and wellness products, leveraging research in stem cell biology, adaptogens, and regenerative nutrition [5]

Steven Pfanstiel, a seasoned financial executive with extensive medical technology and pharmaceutical experience, replaces Steve Furlong as Chief Financial Officer following previously announced succession process Neuronetics reiterates guidance for second quarter and full year 2025 MALVERN, Pa., July 15, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a vertically integrated, commercial stage, medical technology and healthcare company with a strategic vision of transforming the lives of patients ...

"The vast majority of diseases or brain issues, I think are fixable with a Neuralink device."Elon Muskhttps://t.co/FVCBNaPAV5 ...

一水 发自 凹非寺 量子位 | 公众号 QbitAI 疯狂，太疯狂了~ 大神卡帕西预测的 「下一代GUI系统」 这就水灵灵地实现了？！ 玩法相当easy，当你移动鼠标、点击图标或敲键盘时，这个 完全由神经网络驱动的操作系统 就和咱们平时的电脑一样，能在屏幕上实时显示 对应的图形界面。 就是说，AI现在能 完全模拟Windows，直接预测下一帧屏幕图像 。 事实上，卡帕西在今年5月就预言了一波"AI时代的图形用户界面长啥样"。 在他看来，如今和大语言模型（LLM）聊天就像在使用80年代的电脑终端，还没有用上图形用户界面（GUI）。 而在未来，随着AI能力逐渐扩展，GUI将是 为每个用户量身打造的流动（fluid）、魔幻（magical）、可交互（ephemeral）的2D画布，就 像你专属的操作系统，实时重绘、实时响应 。 受此启发，5位来自滑铁卢大学和加拿大国家研究委员会的研究人员提出 NeuralOS ，并打造出了一个可试玩的初版演示demo。 这一最新成果为构建完全自适应的生成式神经接口迈出了重要一步，有望应用于下一代人机交互系统。 那么问题来了—— NeuralOS是靠什么模拟Windows的呢？ 关键 ...

Core Insights - Elon Musk announced a significant demonstration of the Optimus robot (also known as Tesla Bot) is expected by the end of this year, generating speculation about its capabilities [1] - The Optimus project is considered by Musk to have the most potential for everyday consumer use and financial growth among Tesla's ongoing projects [4] Group 1 - Musk indicated that the agility of Optimus 2.5 and 3 will be comparable to that of an agile human [1] - There are indications that the upcoming demonstration may focus on Optimus 3, as suggested by community discussions [1] - Musk's Neuralink company has made updates that allow for complete control of the Optimus robot through its chip, providing access to all sensor data [4] Group 2 - Musk projected that if progress continues smoothly, Tesla's production of humanoid robots could increase tenfold by 2026, with a target of producing 50,000 to 100,000 units next year [4] - The second-generation Roadster has been deprioritized in favor of projects that have a greater impact on global energy transition, as confirmed by Musk during a recent earnings call [4]

计算机 2025 年 07 月 11 日 数据来源：聚源 -22% 0% 22% 43% 65% 86% 2024-07 2024-11 2025-03 计算机 沪深300 相关研究报告 《稳定币和AI产业持续催化—行业周 报》-2025.7.6 《稳定币迎来"奇点"时刻，产业大 趋势已至—行业深度报告》-2025.6.30 《重视稳定币和AI两大产业趋势—行 业周报》-2025.6.29 脑机接口：从概念到落地，开启交互新时代 ——行业深度报告 | 陈宝健（分析师） | 李海强（分析师） | | --- | --- | | chenbaojian@kysec.cn | lihaiqiang@kysec.cn | | 证书编号：S0790520080001 | 证书编号：S0790524070003 | 脑机接口：从概念到落地，静待市场潜力释放 投资评级：看好（维持） 行业走势图 脑机接口下游应用市场潜力大。脑机接口（BCI）是连接大脑与外部设备实现信 息交互的新型技术，广泛应用于疾病预警、诊断、治疗和功能增强等医疗领域及 消费、工业等非医疗领域。麦肯锡预测，全球脑机接口医疗应用市场规模有望在 2030 年达 ...

Group 1 - The core concept of the news is the launch of a physical 4S store by Juwei Technology in Hangzhou, allowing consumers to experience and customize their robotic dog, MOVENEW T1, similar to purchasing a car [1][2] - The MOVENEW T1 robotic dog weighs 60 pounds but can carry loads of up to 220 pounds, exceeding the industry average in load capacity and capable of operating in various terrains such as sand, snow, and stairs [2] - The store offers 36 color options and various shell materials for customization, allowing consumers to create a robotic dog that can transform into different functional tools like a mobile suitcase or a logistics assistant [2] Group 2 - The Qiantang district has been recognized as a key growth area for embodied intelligence, with over 100 AI companies and more than 100 innovation parks, contributing to a robust industrial chain in advanced chips, robotics, intelligent perception, and AI algorithms [3] - The district has initiated the construction of an embodied intelligence future industry pilot zone, focusing on attracting quality enterprises, providing targeted policy support, and creating demonstration scenarios to enhance the integration of innovation, industry, finance, and talent [3]

The latest development is expected to bolster the company's Diabetes Care business. ABT Stock's Likely Trend Following the News Following the announcement, Abbott's shares moved down slightly 0.2%, finishing at $133.36 on Tuesday. On a positive note, Abbott's Diabetes Care business continued to benefit from the growing sales of its flagship, sensor-based continuous glucose monitoring system, FreeStyle Libre. In a relatively short span, FreeStyle Libre has achieved global leadership among continuous glucose ...